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Tonelli et al disagree with our interpretation of the
hospitalization data. While hematocrit and quality of
life were the central focus of our work, we also believe
that the hospitalization rate data suggest a benefit with
epoetin alfa. We look forward to further research to cor-
roborate these findings.
Overall, we would not represent the results in our work
as anything but what they are, a synthesis of the available
evidence with all its strengths and weaknesses. We believe
the criticisms put forth by Tonelli et al stem largely from
a misunderstanding of our article.
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Mycophenolate mofetil in IgA
nephropathy
To the Editor: We wish to raise several issues regard-
ing the publication by Maes et al [1], reporting on the
effectiveness of mycophenolate mofetil (MMF) in IgA
nephropathy (IgAN): (1) A sample of 34 patients is too
little. We have started a randomized trial, ramipril versus
ramipril plus MMF in IgAN [2]: 57 patients per group are
required to maintain a power of 80% and a type error of
5%. For a dropout rate of 10%, a total sample size of
126 patients needs to be enrolled. In the placebo group,
2 patients (1 death, 1 adverse event) out of 13 patients
(15%), and in the MMF group, 8 patients [2 end-stage
renal disease (ESRD), 2 emigrated, 1 adverse event, 1
tuberculosis (TB), 2 gastrointestinal (GI) problems] out
of 21 patients (38%) reduced or stopped the treatment
before the end of the trial.
(2) Inclusion criteria. “Eligible patients were random-
ized (2:1; MMF:placebo).” In a randomized trial all pa-
tients should have the same probability of receiving one
or the other of the treatments being compared [3]. Renal
function for inclusion was taken at the time of diagnosis
(ie, 0 to 5 years back from randomization). Were patients
with glomerular filtration rate (GFR) <20 mL/min in-
cluded? Options for eligibility were also hypertension,
proteinuria, and histologic severity, alone or in combina-
tion. Were these risk factors evenly distributed between
groups?
(3) A wash-out period for patients assuming enalapril
was not performed, biasing proteinuria at entry.
(4) In a small patient sample, data distribution is not
usually normal and a nonparametric approach would
have been more appropriate.
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Reply from the Authors
We agree that, from a statistical point of view, the study
is not powered to prove differences or equivalence be-
tween the two groups. Therefore, large multicenter trials
are warranted. Even a study of 126 patients is small to un-
equivocally prove superiority of mycophenolate mofetil
(MMF) treatment over standard renoprotective treat-
ment (including salt restriction, angiotensin II suppres-
sion) plus frequent follow-up (compliance). Using the
data from our study population, the number of patients
per group after dropout would have to be 83 to maintain
a power of 80% and an a-value of 0.05 [1, 2]. Because that
number could not be reached, a 2:1 randomization was
performed in order to maximize the number of patients
exposed to MMF. We clearly stated this in the abstract
and discussion section of the manuscript.
As stated, patients with GFR <20 mL/min were ex-
cluded, and risk factors did not differ significantly be-
tween groups alone or in combination.
